ESEkta Singh

Ekta Singh

*This is an algorithmically generated author record based on publicly available information.

Ekta Singh has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Asthma: An Overview of Pathophysiology, Molecular Mechanisms and Combination Therapy

    by Sneha S, Ekta Singh

    Asthma is a chronic inflammatory disorder of the respiratory airways that is characterized by narrowing of airways, wheezing, difficulty in respiration, shortness of breath, stiffness in the chest region, and sometimes cough. In some cases, mucus secretion is enhanced. Several factors precipitate asthma. These factors may contribute individually or collectively to the pathophysiology of asthma. The objective of this review is to compile a detailed description of pathways involved in asthma. This compilation helps provide a better understanding of the disease. The information provided in this review may be used for planning a personalized therapy. Besides pathways, this review includes the current therapy used for asthma management. New combinations of drugs targeting multiple pathways can be developed to better manage the disease.

  • Open Access

    In-silico based discovery of potential Keap1 inhibitors using the strategies of pharmacophore screening, molecular docking, and MD simulation studies

    by Ekta Singh, Gurubasavaraja Swamy Purawarga Matada, Prasad Sanjay Dhiwar, Rajesh B. Patil, Rohit Pal

    Introduction: The main objective of this research is to identify potential leads for developing potent Keap1 inhibitors. Methods: In the current research article, in-silico methods have been employed to discover potential Keap1 inhibitors. 3D-QSAR was generated using the ChemBL database of Keap1 inhibitors with IC50. The best pharmacophore was selected for the screening of three different libraries namely Asinex, MiniMaybridge, and Zinc. The molecules screened from the databases were filtered through druggability rules and molecular docking studies. The best binding molecules obtained after docking studies were subjected to physicochemical properties toxicity determination by in-silico methods. The best hits were studied for stability in the cavity of Keap1 by molecular dynamic simulations. Results: The virtual screening of different databases was carried out separately and three leads, were obtained. These lead molecules ASINEX 508, MiniMaybridgeHTS_01719, and ZINC 0000952883 showed the best binding in the Keap1 cavity. The molecular dynamic simulations of the binding complexes of the leads support the docking analysis. The leads (ASINEX 508, MiniMaybridgeHTS_01719, and ZINC 0000952883) were stabilized in the Keap1 binding cavity throughout 100 ns simulation, with average RMSD values of 0.100, 0.114, and 0.106 nm, respectively. Conclusion: This research proposes three lead molecules as potential Keap1 inhibitors based on high throughput screening, docking, and MD simulation studies. These hit molecules can be used for further design and development of Keap1 inhibitors. This research provides the preliminary data for discovering novel Keap1 inhibitors. It opens new avenues for medicinal chemists to explore antioxidant-stimulating molecules targeting the Keap1-Nrf2 pathway.


  • An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review

    by Prasad Sanjay Dhiwar, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, Ekta Singh, Abhishek Ghara, Lalmohan Maji, Sindhuja Sengupta, Ganesh Andhale

    Epidermal growth factor receptor (EGFR) and its subtype human epidermal growth factor receptor 2 (HER2) gets activated when its endogenous ligand(s) bind to its ATP binding site of target receptors. In breast cancer (BC), EGFR and HER2 are two proteins are overexpressed which leads to overexpression of cells proliferation and decreases cell death/apoptosis. Pyrimidine is one of the most widely studied heterocyclic scaffolds for EGFR as well as HER2 inhibition. We gather some remarkable results for fused-pyrimidine derivatives on various cancerous cell lines (in-vitro) and animal (in-vivo) evaluation to highlight their potency. The heterocyclic (five, six-membered, etc.) moieties which are coupled with pyrimidine moiety are potent against EGFR and HER2 inhibitions. Hence structure-activity relationship (SAR) plays important role in study of heterocyclic moiety along pyrimidine and effects of substituents, groups for increase or decrease in the cancerous activity and toxicity. By thoughtful of fused pyrimidines SAR study, it facilitates in receiving excellent overview of the compounds by concerning of efficacy and potential summary for future EGFR inhibitors. Furthermore, we studied the in-silico interactions of synthesized compounds to evaluate binding affinity towards the key amino acids.. Communicated by Ramaswamy H. Sarma


  • Open Access

    A Review on Antioxidant Properties of Extracts Obtained from the Leaf, Stem, Bark and Flower of Calotropis Species

    by Bhoomika S, Ekta Singh

    The extracts obtained from different parts of Calotropis plant have been utilized for various activities. In this review we have compiled different methods used for the extraction of phytoconstituents from various parts of Calotropis. We have compiled the antioxidant studies done on these extracts. This review gives an idea about selection of solvents for extraction of different phytochemicals from Calotropis plant along with the methodologies adopted for antioxidant study of these extracts. Numerous investigations have been carried out to investigate the active chemicals and potential biological activities of Calotropis gigantea. Isolated chemicals from various parts of the plant have been evaluated for their pharmacological effects such as analgesic anthelmintic anti-asthmatic anti-arthritis anti-bacterial anti-cancer anti-convulsive anti-diabetic anti-diarrhoeal anti-histaminic anti-inflammatory anti-pyretic anti-ulcer antihypertensive and antioxidant activity. The pharmacological effects and phytochemistry of Calotropis species are summarized in this review article. This potential herb could be investigated with additional research towards the development of effective medications for a range of therapies.


  • Open Access

    INHIBITORS OF BROMODOMAIN-4 AND CYCLOOXYGENASE-2: A REVIEW ON THE ADVANTAGEOUS EFFECT OF DUAL-TARGET APPROACH IN CANCER TREATMENT

    by Ekta Singh

    The main objective of this review article is to establish a correlation between the roles of BRD-4 and COX-2 inhibitors in anticancer treatment. This article aims to project the synergistic benefits of a dual-target approach. A Literature review was conducted using the keywords such as BRD-4, cyclooxygenase-2, COX-2, Anticancer, anti-proliferative BRD-4 inhibitors, COX-2 inhibitors and dual-target therapy. Searches were made using the mentioned keywords individually as well as in combinations in PubMed, Science Direct and Google Scholar for the past ten years. The correlation between inflammatory mediators, particularly COX-2 and bromodomain in particular BRD-4 in cancers has been studied in a few research articles. These targets have been used for the development of anti-proliferative drugs individually as well as in combination. Combination therapy has been proposed to be better than mono-drug therapy. The need for a dual target concept has arisen to improve the efficacy of chemotherapy. The cancers where BRD-4 is over-expressed and inflammation is observed, it may be very much advantageous to give a combination therapy of BRD-4 and COX-2 inhibitors. Moreover, if the COX-2 inhibitors show anti-proliferative action, then the combination therapy is expected to work better than mono chemotherapy.


  • Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual screening strategy

    by Arka Das, Gurubasavaraja Swamy Purawarga Matada, Prasad Sanjay Dhiwar, Nulgumnalli Manjunathaiah Raghavendra, Nahid Abbas, Ekta Singh, Abhishek Ghara, Ganesh Prasad Shenoy


  • Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer

    by Prasad Sanjay Dhiwar, Gurubasavaraja Swamy Purwarga Matada, Nulgumnalli Manjunathaiah Raghavendra, Abhishek Ghara, Ekta Singh, Nahid Abbas, Ganesh Sakaram Andhale, Ganesh Prasad Shenoy, Pujan Sasmal


  • Pharmacophore modeling, virtual screening, molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach

    by Gurubasavaraja Swamy Purwarga Matada, Prasad Sanjay Dhiwar, Nahid Abbas, Ekta Singh, Abhishek Ghara, Rajesh Patil, Nulgumnalli Manjunathaiah Raghavendra


  • Discovery of potential Aurora-A kinase inhibitors by 3D QSAR pharmacophore modeling, virtual screening, docking, and MD simulation studies

    by Gurubasavaraja Swamy P. M., Nahid Abbas, Prasad Sanjay Dhiwar, Ekta Singh, Abhishek Ghara, Arka Das

    The Aurora-kinase family comprises of cell cycle-regulated serine/threonine kinases playing a vital role during mitosis. Aurora-A kinase is involved in multiple mitotic events in cell cycle and is a major regulator of centrosome function during mitosis. Aurora-A is overexpressed in breast, lung, colon, ovarian, glial, and pancreatic cancer. Hence, Aurora-A kinase is a promising target in cancer therapy. In our current study, a four-point 3D QSAR pharmacophore model has been generated using substituted pyrimidine class of Aurora-A kinase inhibitors. It had a fixed cost value 88.7429. The model mapped well to the external test set comprising of clinically active molecules, with a correlation coefficient r = 0.99. From the mapping, it was found that the hydrophobic features (HY) of a molecule play an important role for Aurora-A kinase inhibitory activity, whereas the ring aromatic feature provides geometric constraint for spatial alignment of different functional group. The hypothesis, with one hydrogen bond acceptor, two ring aromatic features, and one hydrophobic feature, was selected to screen miniMaybridge database. The screened ligands were filtered on the basis of activity, shape, and drug likeliness. This led to the identification of five top hits. These identified potential leads were further subjected to docking with the ATP-binding site of Aurora-A kinase. The molecular dynamic simulation studies of top lead molecules having diverse scaffolds endorsed that the identified molecules had distinctive ability to inhibit Aurora-A kinase. Thus, this study may facilitate the medicinal chemists to design promising ligands with various scaffolds to inhibit Aurora-A kinase. Communicated by Ramaswamy H. Sarma Graphical Abstract


  • Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review

    by Ekta Singh, Gurubasavaraja Swamy Purawarga Matada, Nahid Abbas, Prasad Sanjay Dhiwar, Abhishek Ghara, Arka Das

    The natural pathway of antioxidant production is mediated through Kelch-like erythroid cell-derived protein with Cap and collar homology [ECH]-associated protein 1 (Keap1)-Nuclear factor erythroid 2-related factor 2 (Nrf2) system. Keap1 maintains a low level of Nrf2 by holding it in its protein complex. Also, Keap1 facilitates the degradation of Nrf2 by ubiquitination. In other words, Keap1 is a down-regulator of Nrf2. To boost the production of biological antioxidants, Keap1 has to be inhibited and Nrf2 has to be released. Liberated Nrf2 is in an unbound state, so it travels to the nucleus to stimulate the antioxidant response element (ARE) present on the antioxidant genes. AREs activate biosynthesis of biological antioxidants through genes responsible for the production of antioxidants. In some cases of coronavirus disease 2019 (COVID-19), there is an enormous release of cytokines. The antioxidant defense mechanism in the body helps in counteracting symptoms induced by the cytokine storm in COVID-19. So, boosting the production of antioxidants is highly desirable in such a condition. In this review article, we have compiled the role of Keap1-Nrf2 system in antioxidant production. We further propose its potential therapeutic use in managing cytokine storm in COVID-19. Graphic abstract